(A) MCs were treated with 100 nM PTHrP (1–34) for indicated period, and EGFR phosphorylation at Y845 and Akt phosphorylation at S473 were detected by western blot (*P<0.05 vs control, n=4). (B) MCs were pretreated with specific EGFR kinase inhibitor, AG1478 or Gefitinib, before PTHrP (1–34) incubation for 1 h. Akt phosphorylation at S473 was assessed by western blot (*P<0.05 vs control, n=3). (C) MCs were treated with 100 nM PTHrP (1–34) for indicated durations, and Src phosphorylation at Y416 was detected by western blot (*P<0.05 vs control, n=4). (D) MCs were pretreated with specific Src inhibitor, PP1, or SU6656, prior to PTHrP (1–34) treatment for 1 h. EGFR phosphorylation at Y845 and Akt phosphorylation at S473 were assessed by western blot (*P<0.05 vs control, n=4).